Russian Federation
Tula, Tula, Russian Federation
The review examines the effect of symptomatic delayed-acting drugs, nonsteroidal anti-inflammatory drugs, hyaluronic acid on the course and progression of osteoarthritis.
nonsteroidal anti-inflammatory drugs, symptomatic delayed-action drugs, chondroitin, glucosamine, hyaluronic acid.
1. Lila A.M., Alekseeva L.I., Taskina E.A. Sovremennye podhody k terapii osteoartrita s uchetom obnovlennyh mezhdunarodnyh rekomendaciy. RMZh. Medicinskoe obozrenie. 2019;11(2):48-52.
2. Kovari E., Kaposi A., Bekes G. et al. Comorbidity clusters in generalized osteoarthritis among female patients: A cross-sectional study. Semin Arthritis Rheum. 2019 Sep 9. pii: S0049-0172(19)30233-1. DOI:https://doi.org/10.1016/j.semarthrit.2019.09.001.
3. Drozdov V.N., Shih E.V., Lazareva N.B. Vozmozhnosti snizheniya riska NPVP-gastropatii u bol'nyh osteoartritom. RMZh. 2019;(12):74-78.
4. Shavlovskaya O.A., Kuznecov S.L. In'ekcionnaya forma hondroitina sul'fata v nevrologicheskoy praktike. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2019;119(5):126-133.
5. Lo Y.L., Sung K.H., Chiu C.C., Wang L.F. Chemically conjugating polyethylenimine with chondroitin sulfate to promote CD44-mediated endocytosis for gene delivery. Mol Pharm. 2013Feb 4;10(2):664-676. DOI:https://doi.org/10.1021/mp300432s. Epub 2013 Jan 14.
6. Duhanin A.S. Simptom-modificiruyuschie preparaty zamedlennogo deystviya v lechenii osteoartrita: ot molekuly k klinicheskomu effektu (vzglyad farmakologa). Sovremennaya revmatologiya. 2018;12(2):79-87. DOI:https://doi.org/10.14412/1996-7012-2018-2-79-87.
7. Balunov P.A. Sravnitel'nyy analiz primeneniya razlichnyh variantov dopolnitel'noy farmakoterapii pri bolyah v spine. Medicinskiy sovet. 2018(6):44-49.
8. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N., Emberson J. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779. DOI:https://doi.org/10.1016/S0140-6736(13)60900-9.
9. Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N., Emberson J. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769-779. DOI:https://doi.org/10.1016/S0140-6736(13)60900-9.
10. Curtis E., Fuggle N., Shaw S. et al. Safety of cyclo-oxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl. 1):25-44. DOIhttps://doi.org/10.1136/bmj.325.7365.619.
11. Karateev A.E., Nasonov E.L., Ivashkin V.T. i dr. Racional'noe ispol'zovanie nesteroidnyh protivovospalitel'nyh preparatov. Klinicheskie rekomendacii. Nauchno-prakticheskaya revmatologiya. 2018;56(Pril 1):1-29. doi.org/10.14412/rjtao20180.
12. Bally M., Beauchamp M.E., Abrahamowicz M. et al. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure. Pharmacoepidemiol Drug Saf. 2018;27(1):69-77. DOI:https://doi.org/10.1002/pds.4358.
13. Julovi SM, Yasuda T, Shimizu M, et al. Inhibition of interleukin-1beta-stimulated production of matrix metalloproteinases by hyaluronan via CD44 in human articular cartilage. Arthritis Rheum. 2004 Feb;50(2):516-25. doi:https://doi.org/10.1002/art.20004.
14. Gotoh S, Onaya J, Abe M, et al. Effects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats. Ann Rheum Dis. 1993;52(11): 817-822. doi:https://doi.org/10.1136/ard.52.11.817.
15. Pena Ede L, Sala S, Rovira JC, et al. Elastoviscous substances with analgesic effects on joint pain reduce stretch-activated ion channel activity in vitro. Pain. 2002;99(3):501-508. doi:https://doi.org/10.1016/S0304-3959(02)00260-9
16. Bannuru RR, Natov NS, Dasi UR, et al. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis--meta-analysis. Osteoarthritis Cartilarge. 2011 Jun;19(6):611-9. doi:https://doi.org/10.1016/j.joca.2010.09.014.
17. Alekseeva LI, Sharapova EP, Zayceva EM i dr. Rezul'taty mnogocentrovogo godichnogo issledovaniya preparata d'yuralan. Effektivnaya farmakoterapiya. 2011;(37):50-7.
18. Bannuru R.R., Osani M.C., Vaysbrot E.E. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019 Nov;27(11):1578-1589. DOI:https://doi.org/10.1016/j.joca.2019.06.011.
19. Wang Z.Y., Shi S.Y., Li S.J. et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials. Pain Med 2015;16(7):1373-1385. DOI:https://doi.org/10.1111/pme.12800.
20. Uchio Y., Enomoto H., Alev L. et al. A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis. J Pain Res. 2018;11:809-821. DOI:https://doi.org/10.2147/JPR.S164128. eCollection 2018.
